The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria - A, C, W and Y, the company ...

T he U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old.Previously ...

A single booster shot of MenQuadfi can be given to people ages 13 years or older who are at a continued risk of IMD if it’s been at least three years since their last meningococcal vaccine.

The FDA has recently approved MenQuadfi, a meningococcal conjugate vaccine that protects against serogroups A, C, Y and W. The approval is for patients aged 2 years and older, according to a press ...

DUBLIN, June 15, 2020 /PRNewswire/ -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering.

European Commission approves MenQuadfi ®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older EC approval based on robust data from seven ...

(RTTNews) - French pharma major Sanofi (SNYNF, SNY) announced Thursday that the U.S. Food and Drug Administration has accepted for review the Biologics License Application or BLA for MenQuadfi ...

MenQuadfi is expected to be available in 2021. The product will be supplied as 0.5mL single-dose, ready-to-use vials in packages of 5. For more information visit sanofi.us .

The immunogenicity and safety of MenQuadfi were evaluated in over 6,300 healthy individuals aged 12 months and older, who received a single dose of MenQuadfi. 1,2,3,4,5,6,7 MenQuadfi was compared with ...

The Food and Drug Administration (FDA) has approved MenQuadfi TM Meningococcal (Groups A, C, Y, W; Sanofi Pasteur) Conjugate Vaccine for the prevention of invasive meningococcal disease caused by ...